Biogen agrees to acquire Apellis Pharmaceuticals for five point six billion dollars to expand immunology portfolio

Mar 31, 2026, 5:18:20 PM UTC(3 hours ago)

Impact: High

Affected Assets

Biogen will pay forty-one dollars per share in cash representing a premium of approximately one hundred forty percent to the previous closing price
The deal includes a contingent value right for shareholders tied to future sales milestones of the eye disorder drug Syfovre
Acquisition adds two FDA-approved medicines to Biogen's portfolio which generated six hundred eighty-nine million dollars in revenue during 2025
The transaction is expected to close in the second quarter of 2026 and become accretive to earnings per share starting in 2027
Analysts view the move as a strategic effort by Biogen to diversify beyond its slowing multiple sclerosis franchise into nephrology and rare diseases

$APLS skyrockets 135.66% after $BIIB agreed to buy the company for $5.6 billion. 📈 https://t.co/uTBJy1Sddz